Lipid-Lowering Therapy and Risk of Coronary Events [2] (multiple letters)

JAMA

Volumn 289, Issue 16, 2003, Pages 2070-2072

  Taylor, William C ^a   Blakely, John A ^b   Mascitelli, Luca ^c   Pezzetta, Francesca ^d   Lardinois, Claude K ^e   Probstfield, Jeffrey L ^f  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b S and Women's Coll Hlth Sci Ctr   (Canada)

^c Casa di Cura Città di Udine   (Italy)

^d Ospedale San Michele   (Italy)

^e UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; PRAVASTATIN; STATINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

AGE DISTRIBUTION; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DOSE RESPONSE; DRUG INDICATION; FOLLOW UP; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LETTER; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; TREATMENT OUTCOME; HYPERCHOLESTEROLEMIA; HYPERTENSION; NOTE; RISK;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; PRAVASTATIN; RISK; RISK FACTORS;

EID: 0346125440     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.16.2070-a     Document Type: Letter

References (0)